Volume 23, Number 10—October 2017
Research
Poliovirus Excretion in Children with Primary Immunodeficiency Disorders, India
Table 3
Serial no. | Age, mo/ sex | PID type | Months from last OPV† | IVIG therapy | BMT | Results by collection day |
---|---|---|---|---|---|---|
1 | 114/F | IgG subclass deficiency | 60 | Yes | ND | D1, neg; D62, EV75; D214,neg; D250, neg; D419, neg; D476, neg; D685, neg |
2 | 42/M | Hyper-IgE syndrome | 24 | No | ND | D1, E13; lost to follow-up |
3 | 18/M | BENTA disease | NA | No | ND | D1, E5; D185, neg; D273, neg |
4 | 30/M | CGD | NA | No | ND | D1, E14; D10, died |
5 | 54/M | XLA | 1 | Yes | ND | D1, EV76; D107, neg; D136, neg; D260, neg |
*BENTA, B cell expansion with NF-κB and T cell anergy; BMT, bone marrow transplant; CGD, chronic granulomatous disease; D, day of collection following first collection; E5, echovirus 5; E13, echovirus 13; E14, echovirus 14; EV75, enterovirus 75; EV76, enterovirus 76; IVIG, intravenous immunoglobulin; NA, not available; ND, not done; neg, negative; OPV, oral polio vaccine; PID, primary immunodeficiency disease; XLA, X-linked agammaglobulinemia.
†Time from last OPV to first fecal sample collection.
Page created: September 18, 2017
Page updated: September 18, 2017
Page reviewed: September 18, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.